Percutaneous double-valve balloon valvotomy for multivalve stenosis: Immediate results and intermediate-term follow-up

Ten patients each with combined mitral and tricuspid stenosis (group 1) and with combined mitral and aortic stenosis (group 2) underwent double-valve balloon valvotomy as a single staged procedure. The aortic valve was dilated by the Mansfield balloon technique, whereas the mitral and tricuspid valves were dilated with either the Mansfield or Inoue balloon. The mitral valve area increased from 0.78 ± 0.21 cm 2 to 2.05 ± 0.56 cm 2 ( p < 0.0005) in group 1 and from 0.75 ± 0.20 cm 2 to 2.1 ± 0.59 cm 2 ( p < 0.05) in group 2. The tricuspid valve area increased from 1.11 ± 0.41 cm 2 to 2.52 ± 0.69 cm 2 ( p < 0.0005). In group 2, the transaortic gradient decreased from 93.56 ± 17.7 mm Hg to 28.56 ± 7.8 mm Hg ( p < 0.0005) and the valve area increased from 0.37 ± 0.05 cm 2 to 1.03 ± 0.25 cm 2 ( p < 0.005). The excellent symptomatic and hemodynamic results were sustained at 30.3 ± 9.8 months of follow-up in group 1 and at 23.5 ± 9.1 months in group 2. Double-valve balloon valvotomy is feasible and safe and provides excellent immediate and intermediate-term follow-up results in selected patients with multivalve disease. A longer follow-up in a larger number of cases is needed to define further the role of this therapy. (Am Heart J 1997;133:64-70.)